A novel monoclonal antibody specific for canine CD25 (P4A10): Selection and evaluation of canine Tregs

Veterinary Immunology and Immunopathology

Volumn 135, Issue 3-4, 2010, Pages 257-265

  Abrams, V Kraig ^a   Hwang, Billanna ^a   Lesnikova, Marina ^a   Gass, M John ^a   Wayner, Elizabeth ^a   Castilla Llorente, Cristina ^a   Georges, George E ^a,b   Nash, Richard A ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cd25; Dog; Monoclonal antibody; Regulatory T cells

Indexed keywords

ALLOANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; IONOMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P4A10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOG; FEMALE; FLOW CYTOMETRY; MALE; MIXED LYMPHOCYTE REACTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BASE SEQUENCE; BINDING, COMPETITIVE; BLOTTING, WESTERN; DNA PRIMERS; DOGS; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; T-LYMPHOCYTES, REGULATORY;

ANIMALIA; CANIS FAMILIARIS;

EID: 77952549040     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.12.006     Document Type: Article

References (37)

1. Arias R.S., Flanagan M.L., Miller K.D., Nien Y.C., Hu P., Gray D., Khawli L.A., Epstein A.L. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma 2007, 26:119-130.
2. Battaglia M., Gregori S., Bacchetta R., Roncarolo M.G. Tr1 cells: from discovery to their clinical application (Review). Seminars in Immunology 2006, 18:120-127.
3. Bielekova B., Richert N., Howard T., Blevins G., Markovic-Plese S., McCartin J., Frank J.A., Wurfel J., Ohayon J., Waldmann T.A., McFarland H.F., Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta [erratum appears in Proc Natl Acad Sci USA. 2004 December 14;101(50):17565]. Proceedings of the National Academy of Sciences 2004, 101:8705-8708.
4. Bien E., Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review (Review). Biomarkers 2008, 13:1-26.
5. Biller B.J., Elmslie R.E., Burnett R.C., Avery A.C., Dow S.W. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Veterinary Immunology and Immunopathology 2007, 116:69-78.
6. Busse W.W., Israel E., Nelson H.S., Baker J.W., Charous B.L., Young D.Y., Vexler V., Shames R.S. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine 2008, 178:1002-1008.
7. Galkowska H., Waldemar L.O., Wojewodzka U. Reactivity of antibodies directed against human antigens with surface markers on canine leukocytes. Veterinary Immunology and Immunopathology 1996, 53:329-334.
8. Gansuvd B., Asiedu C.K., Goodwin J., Jargal U., Deckard L.A., Andrades P., Guarcello V., Thomas J.M. Expansion of CD4+CD25+ suppressive regulatory T cells from rhesus macaque peripheral blood by FN18/antihuman CD28-coated Dynal beads. Human Immunology 2007, 68:478-490.
9. Hagg D.S., Junghans R.P. Measurement and biological correlates of antibody bioactivity during antibody immunotherapies. Journal of Immunological Methods 1998, 219:7-21.
10. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
11. Kaser T., Gerner W., Hammer S.E., Patzl M., Saalmuller A. Phenotypic and functional characterisation of porcine CD4(+)CD25(high) regulatory T cells. Veterinary Immunology and Immunopathology 2008, 122:153-158.
12. Lankford S., Petty C., LaVoy A., Reckling S., Tompkins W., Dean G.A. Cloning of feline FOXP3 and detection of expression in CD4+CD25+ regulatory T cells. Veterinary Immunology and Immunopathology 2008, 122:159-166.
13. Leonard W.J., Depper J.M., Uchiyama T., Smith K.A., Waldmann T.A., Greene W.C. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature 1982, 300:267-269.
14. Lesnikova M., Nikitine A., Mason N., Nash R.A., Georges G.E. Ex vivo expanded T regulatory (Treg) cells block conversion of mixed chimeras to complete donor chimerism. Blood 2006, 108(Part 2):382b. #5168 (Abstract).
15. + regulatory T cells (Treg) with artificial antigen presenting cells (aAPC). Blood 2005, 106(Part 1):867a. #3102 (Abstract).
16. Masuda K., Yasuda N. The antibody against human CD25, ACT-1, recognizes canine T-lymphocytes in the G2/M and G0/G1 phases of the cell cycle during proliferation. Journal of Veterinary Medical Science 2008, 70:1285-1287.
17. Morris J.C., Waldmann T.A. Advances in interleukin 2 receptor targeted treatment (Review). Annals of the Rheumatic Diseases 2000, 59(Suppl. 1):i109-i114.
18. Nash R.A., Yunusov M., Abrams K., Hwang B., Castilla-Llorente C., Chen P., Farivar A.S., Georges G.E., Hackman R.C., Lamm W.J.E., Lesnikova M., Ochs H.D., Randolph-Habecker J., Ziegler S.F., Storb R., Storer B., Madtes D.K., Glenny R., Mulligan M.S. Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation. American Journal of Transplantation 2009, 9:1037-1047.
19. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., Soulillou J.P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [erratum appears in Lancet 1997 November 15;350(9089):1484]. Lancet 1997, 350:1193-1198.
20. Nolte-'t Hoen E.N., Boot E.P., Wagenaar-Hilbers J.P., van Bilsen J.H., Arkesteijn G.J., Storm G., Everse L.A., van Eden W., Wauben M.H. Identification and monitoring of effector and regulatory T cells during experimental arthritis based on differential expression of CD25 and CD134. Journal of Leukocyte Biology 2008, 83:112-121.
21. Oh U., Blevins G., Griffith C., Richert N., Maric D., Lee C.R., McFarland H., Jacobson S. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Archives of Neurology 2009, 66:471-479.
22. Oi V.T., Herzenberg L.A. Immunoglobulin-producing hybrid cell lines. Selected Methods in Cellular Immunology 1980, 351. W.H. Freeman, San Francisco, CA. B.B. Mishell, S.M. Shiigi (Eds.).
23. Peeters D., Peters I.R., Clercx C., Day M.J. Quantification of mRNA encoding cytokines and chemokines in nasal biopsies from dogs with sino-nasal aspergillosis. Veterinary Microbiology 2006, 114:318-326.
24. Roncarolo M.G., Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? (Review). European Journal of Immunology 2008, 38:925-927.
25. Rose J.W., Burns J.B., Bjorklund J., Klein J., Watt H.E., Carlson N.G. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007, 69:785-789.
26. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology 1995, 155:1151-1164.
27. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
28. Schweighoffer T., Tanaka Y., Tidswell M., Erle D.J., Horgan K.J., Luce G.E., Lazarovits A.I., Buck D., Shaw S. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism. Journal of Immunology 1993, 151:717-729.
29. Taggart R.T., Samloff I.M. Stable antibody-producing murine hybridomas. Science 1983, 219:1228-1230.
30. Van Assche G., Sandborn W.J., Feagan B.G., Salzberg B.A., Silvers D., Monroe P.S., Pandak W.M., Anderson F.H., Valentine J.F., Wild G.E., Geenen D.J., Sprague R., Targan S.R., Rutgeerts P., Vexler V., Young D., Shames R.S. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006, 55:1568-1574.
31. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., Neylan J., Wilkinson A., Ekberg H., Gaston R., Backman L., Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. New England Journal of Medicine 1998, 338:161-165.
32. Waldmann T.A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma (Review). Oncogene 2007, 26:3699-3703.
33. Walker M.R., Carson B.D., Nepom G.T., Ziegler S.F., Buckner J.H. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+ CD25- cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:4103-4108.
34. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., Ziegler S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+ CD25- T cells. Journal of Clinical Investigation 2003, 112:1437-1443.
35. Wayner E.A., Hoffstrom B.G. Development of monoclonal antibodies to integrin receptors (Review). Methods in Enzymology 2007, 426:117-153.
36. Wijdenes J., Roy C., Morel-Fourrier B., Racadot E. Monoclonal antibodies in human organ transplantation and auto-immune diseases (Review). Therapie 1992, 47:283-287.
37. Yeh S., Wroblewski K., Buggage R., Li Z., Kurup S.K., Sen H.N., Dahr S., Sran P., Reed G.F., Robinson R., Ragheb J.A., Waldmann T.A., Nussenblatt R.B. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. Journal of Autoimmunity 2008, 31:91-97.